Special Issue "Role of ABC Transporters in Drug Development"

A special issue of Pharmaceutics (ISSN 1999-4923). This special issue belongs to the section "Drug Targeting and Design".

Deadline for manuscript submissions: 30 October 2023 | Viewed by 98

Special Issue Editor

Department of Biophysics and Cell Biology, Faculty of Medicine, University of Debrecen, H-4032 Debrecen, Hungary
Interests: ABCB1; ABCG2; substrate–transporter interactions; catalytic cycle; fluorescence-based techniques

Special Issue Information

Dear Colleagues,

This Special Issue of Pharmaceutics aims to cover the interactions between ABC (ATP-binding cassette) transporters and chemotherapeutic drugs or drug candidates developed for the treatment of various diseases. The majority of human ABC proteins are plasma membrane efflux transporters that can restrict the penetration of amphiphilic or lipophilic small molecules through cellular and tissue barriers and thereby affect the pharmacological and toxicological profile of numerous chemotherapeutic drugs and drug candidates. When expressed in tumor cells or tumor stem cells, ABC transporters can confer multidrug resistance and contribute to the failure of cancer chemotherapy. Since several ABC transporters are expressed in the blood–brain barrier and in different cells of the central nervous system, they can affect the chemotherapy of neurological diseases such as Alzheimer’s and Parkinson’s, depression, schizophrenia and epilepsy, among others. Drug–drug interactions occurring on the level ABC transporters often modify the absorption or elimination of chemotherapeutic drugs and may lead to toxicity and serious side-effects. These are just some examples supporting the importance of ABC transporters in drug development. This Issue would like to provide a collection of original research and review papers to help in the further advancement of potential clinical applications. I look forward to receiving your contributions.

Dr. Katalin Goda
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.


  • ABC transporters
  • pharmacological barriers
  • drug–drug interactions on the level ABC transporters
  • ABC transporters in the treatment of neurological diseases

Published Papers

This special issue is now open for submission.
Back to TopTop